HC Wainwright Issues Optimistic Forecast for AVDL Earnings

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) – Research analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for shares of Avadel Pharmaceuticals in a research note issued on Friday, September 5th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.17 per share for the quarter, up from their previous estimate of $0.13. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals’ Q2 2026 earnings at $0.19 EPS and Q4 2026 earnings at $0.26 EPS.

Other equities analysts have also recently issued research reports about the company. UBS Group lifted their price target on Avadel Pharmaceuticals from $13.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, August 21st. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Avadel Pharmaceuticals in a research note on Friday, August 8th. Wall Street Zen upgraded Avadel Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Zacks Research raised shares of Avadel Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 8th. Finally, Lifesci Capital raised shares of Avadel Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, September 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $20.86.

Avadel Pharmaceuticals Price Performance

Avadel Pharmaceuticals stock opened at $15.59 on Monday. The company’s 50-day moving average is $12.26 and its 200-day moving average is $9.85. The firm has a market capitalization of $1.51 billion, a PE ratio of -519.67 and a beta of 1.58. Avadel Pharmaceuticals has a fifty-two week low of $6.38 and a fifty-two week high of $16.66.

Avadel Pharmaceuticals (NASDAQ:AVDL) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.08. The firm had revenue of $68.13 million for the quarter, compared to analyst estimates of $60.28 million. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. The company’s quarterly revenue was up 64.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.14) earnings per share. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Kovack Advisors Inc. grew its position in Avadel Pharmaceuticals by 13.0% in the second quarter. Kovack Advisors Inc. now owns 13,000 shares of the company’s stock valued at $115,000 after acquiring an additional 1,500 shares during the last quarter. Creative Planning boosted its stake in shares of Avadel Pharmaceuticals by 10.0% in the 2nd quarter. Creative Planning now owns 19,376 shares of the company’s stock valued at $171,000 after purchasing an additional 1,759 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Avadel Pharmaceuticals by 3.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 52,594 shares of the company’s stock valued at $553,000 after purchasing an additional 1,882 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Avadel Pharmaceuticals by 164.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $29,000 after purchasing an additional 2,055 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd increased its position in Avadel Pharmaceuticals by 18.8% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 17,439 shares of the company’s stock worth $154,000 after purchasing an additional 2,761 shares in the last quarter. Institutional investors own 69.19% of the company’s stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.